A conservative domain shared by HIV gp120 and EIAV gp90: Implications for HIV vaccine design

AIDS Research and Human Retroviruses

Volumn 21, Issue 12, 2005, Pages 1057-1059

  Li, Huiguang ^a   Zhang, Xiaoyan ^a   Fan, Xiujuan ^a   Shen, Tao ^a   Tong, Xiao ^a   Shen, Rongxian ^a   Shao, Yiming ^a  

^a Chinese Center for Diseases Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 90; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; EQUINE INFECTIOUS ANEMIA VIRUS; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETROVIRUS;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CONSERVED SEQUENCE; DRUG DESIGN; EPITOPES, B-LYMPHOCYTE; GLYCOPROTEINS; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HORSES; HUMANS; MOLECULAR SEQUENCE DATA; VIRAL ENVELOPE PROTEINS;

EID: 30344442434     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.1057     Document Type: Article

References (10)

1. Shen RX, Xu ZD, and He YS: Immunology study on equine anemia infectious disease. Chin Sci Agric 1979;12:1-15.
2. Hotzel I: Conservation of the human immunodeficiency virus type 1 gp120 V1/V2 stem/loop structure in the equine infectious anemia virus (EIAV) gp90. AIDS Res Hum Retroviruses 2003;19:923-924.
3. Leonard CD, Spellman MW, Riddle L, et al.: Assignment of intra-chain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
4. McKeating JA, Shotton C, Cordell J, et al.: Characterization of neutralizing monoclonal antibodies of linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993;67:4932-4944.
5. Susan Z: Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004;4:199-210.
6. Ball JM, Rushlow K, Issel JC, et al.: Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol 1992;66:732-742.
7. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
8. Leroux C, Cadore JL, and Montelaro RC: Equine infectious anemia virus (EIAV): What has HIVs country cousin got to tell us? Vet Res 2004;35:485-512.
9. He X: Construction of infectious EIAV Chimeric clones and studies of their characteristics. Thesis of Chinese Center of AIDS and STD Control and Prevention, 2002.
10. Dai CM, Zhang XY, Shao YM, et al.: Expression of EIAV gp90 in vaccinia and studies on its immunological characteristics. Virol Sin 2003;18:473-477.